Ginkgolide B is the strongest platelet activating factor antagonist found so far. It can be used in the clinical treatment of thrombosis, acute pancreatitis and cardiovascular disease, as well as in the treatment of metastatic cancer. The efficacy is better than that of total lactones, and the price is also much higher than that of total lactones. Ginkgolide B has protective effects on immune system, central nervous system and ischemic injury, and has anti shock, anti allergy and anti-inflammatory effects. It also has anti allergic effect, protects intestinal tract and intestinal mucosa, prevents migraine and treats Alzheimer's disease. Therefore, Ginkgolide B has important clinical application possibility.
The development of Ginkgo biloba products abroad began in the 1970s. German Schwabe company first used the patented solvent extraction technology to produce standard Ginkgo biloba extract and developed corresponding preparations. Now Ginkgo biloba preparation has become the preferred natural drug for the treatment of cardiovascular and cerebrovascular diseases, and its dosage is increasing year by year; There are more than 40 kinds of Ginkgo drugs and health products, with an annual output value of more than 3billion yuan. These drugs have shown unique efficacy in the treatment of cardiovascular and cerebrovascular diseases. After years of clinical application, their safety and effectiveness have been widely recognized.
At present, Ginkgo biloba drugs used in clinical practice are mainly compound preparations with effective parts. With the identification of effective medicinal ingredients in Ginkgo biloba leaves, new drugs with single effective ingredient have become the target of competitive development in France, Britain, Germany and the United States in the past 10 years. The mixed preparation of ginkgolide A, B and C has entered the phase III clinical study, applied to the treatment of asthma, and evaluated its effectiveness in the treatment of septic shock, cerebral ischemia, kidney transplantation and burn patients. In China, the preparation based on the active ingredient Ginkgolide B is also under development.
These new preparations may further improve the efficacy, improve the safety of medication, make it easier to control the quality of drugs, and have more prospects for clinical application. Especially in the treatment of cerebrovascular diseases, 11.3% of the 57 countries surveyed by who died of cerebrovascular diseases, of which 40 countries ranked among the top 3 causes of death. Large drug doses are often required for the treatment of emergencies, but the dose-response relationship of natural drugs of some effective parts is not stable enough, which affects the selection of clinical doses. Ginkgolide B is a fat soluble substance, which can smoothly pass through the blood-brain barrier. The clinical trial of Ginkgolide B injection independently developed in China has preliminarily proved that the drug can treat ischemic encephalopathy including acute ischemic cerebral infarction, and is expected to become a new choice for the treatment of acute ischemic diseases.
In recent years, withGinkgolide BWith the further study of pharmacological effects, through the study of the effects of Ginkgolide B on the sequence of oocytes, fertilization and embryo development of mature mice, it was found that Ginkgolide B can stimulate and inhibit apoptosis signals, induce mouse blastocyst development, increase early blastocyst death and affect embryo development. Therefore, in practical application, it is also necessary to pay attention to taboos and not to use them at will.